Benjamin Hohl - 22 Dec 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Benjamin Hohl
Issuer symbol
ELVN
Transactions as of
22 Dec 2025
Net transactions value
+$32,240
Form type
4
Filing time
23 Dec 2025, 18:47:17 UTC
Previous filing
01 Oct 2025
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hohl Benjamin CHIEF FINANCIAL OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Benjamin Hohl 23 Dec 2025 0001882764

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $32,240 +13,000 +57% $2.48 36,000 22 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -13,000 -12% $0.000000 92,056 22 Dec 2025 Common Stock 13,000 $2.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All of the shares subject to this option are fully vested and exercisable as of the date hereof.